Akiyoshi T, Arinaga S, Nanbara S, Karimine N, Inoue H, Takamuku K, Abe R, Watanabe D, Nagamatsu M, Matsuoka H
Department of Surgery, Kyushu University, Beppu, Japan.
Jpn J Surg. 1990 May;20(3):365-8. doi: 10.1007/BF02470676.
We recently discovered that the ability of cancer patients to generate lymphokine-activated killer (LAK) cells became remarkably augmented after mitomycin C (MMC) administration. Based on our clinical findings, we designed a treatment regimen comprised of MMC 12 mg/m2 given intravenously on day 1 and recombinant interleukin 2 (rIL 2) 700 U/m2 given intravenously every 12 hr from day 4 through day 8, when the generation of LAK cells had been shown to be markedly increased. Ten patients with various advanced carcinomas for which standard therapy had failed or no standard therapy was available, were treated with this regimen. Of these ten, three had a partial response and three others had a minor response. Fevers were common and anemia occurred in four patients, but nevertheless, severe toxicity was not encountered. These results indicated that rIL 2 in combination with MMC might be effective against advanced carcinoma without causing severe toxicity when these drugs are used in an appropriate combination.
我们最近发现，癌症患者在使用丝裂霉素C（MMC）后产生淋巴因子激活的杀伤（LAK）细胞的能力显著增强。基于我们的临床发现，我们设计了一种治疗方案，包括第1天静脉注射MMC 12 mg/m²，从第4天到第8天每12小时静脉注射重组白细胞介素2（rIL 2）700 U/m²，此时已显示LAK细胞的生成明显增加。10例标准治疗失败或无标准治疗方案的晚期癌症患者接受了该方案治疗。这10例患者中，3例部分缓解，另外3例轻微缓解。发热很常见，4例患者出现贫血，但未出现严重毒性反应。这些结果表明，当rIL 2与MMC以适当组合使用时，可能对晚期癌症有效且不会引起严重毒性。
